α-interferon inhibits the development of diabetes in NOD mice

Diabetes

Volumn 47, Issue 12, 1998, Pages 1867-1872

  Sobel, Douglas O ^a   Ahvazi, Behrouz ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031737908     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.12.1867     Document Type: Article

References (41)

1. Makino S, Tochino Y: The spontaneously nonobese diabetic mouse. Exp Anim 27:27-29, 1978
2. Kikutani H, Makino S: The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51:285-322, 1992
3. Manignat L, Elmansour A, Audrain M, Julien JF, Charbonnel B, Sai P: Pan- creatic expression of antigens for islet cell antibodies in nonobese diabetic mice. J Autoimmunity 8:465-482, 1995
4. Kanazawa Y, Komeda K, Sato S, Mori S, Akanuma K, Takaku F: Nonobese diabetic mice: immune mechanisms of pancreatic β-cell destruction. Diabetologia 27 (Suppl.):113-115, 1984
5. Bernard NF, Ertug F, Margolese H: High incidence of thyroiditis and anti-thyroid antibodies autoantibodies in NOD mice. Diabetes 41:40-46, 1992
6. Koike T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36:539-541, 1987
7. Stiller CR, Dupre J, Gent M, Heinrichs D, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, Wolfe BM: Effects of cyclosporin in recent-onset juvenile type 1 diabetes mellitus: impact of age and duration of disease. J Pediatr 111:1069-1072, 1987
8. Baron S, Coppenhaver DH, Dianzani F, Fleischmann RW, Hughes TK Jr, Klampel GR, Niesel DW, Stanton GJ, Tyring SK: Interferon: Principles and Medical Applications. Galveston, TX, University of Texas Medical Branch Press, 1992, p. 624
9. Lindahl P, Leary P, Gresser I: Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69:721-725, 1972
10. Chen BD, Najor F: Macrophage activation by interferon-α and -β is associated with a loss of proliferative capacity: role of interferon-α and -β in the regulation of macrophage proliferation and function. Cell Immunol 106:343-354, 1987
11. Morikawa K, Kubagawa H, Suzuki T, Cooper MD: Recombinant interferon-alpha, -beta, and -gamma enhance the proliferation of human B-cells. J Immunol 139:761-766, 1987
12. Adam C, Thoua YT, Ronco P, Verroust P, Tovey M, Morel-Maroger L: The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 40:373-382, 1980
13. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ: Induction of type 1 diabetes by interferon-α in transgenic mice. Science 260:1942-1946, 1993
14. Huang X, Hultgren B, Dybdal N, Stewart TA: Islet expression of interferon-α precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1:469-478, 1994
15. Foulis AK, Farquharson MA, Meager A: Immunoreactive alpha-interferon in insulin-secreting beta cells in type I diabetes mellitus. Lancet ii: 1423-1427, 1987
16. Huang X, Yuang J, Goddard A, Foulis A, James RF, Lernmark A, Pugol-Borrell R, Rabinovitch A, Somoza N, Stewart TA: Interferon expression in the pancreases of patients with type 1 diabetes. Diabetes 44:658-664, 1995
17. Dyrberg T, Schwimmbeck PL, Oldstone MB: Inhibition of diabetes in BB rats by virus infections. J Clin Invest 81:928-931, 1988
18. Oldstone MB: Prevention of type 1 diabetes in NOD mice by virus infection. Science 239:500-502, 1988
19. Isaacs A, Lindenmann, J: Virus interference. I. The Interferon. Proc R Soc Lond Biol Sci 147:258-267, 1957
20. Sobel DO, Creswell K, Yoon J-W, Holterman D: Alpha-interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Science 62:1293-1302, 1998
21. Rehberg E, Kelder B, Hoal EG, Peska S: Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 257:11497-11502, 1982
22. Welsh RM, Karre K, Hansson M, Kunkel LA, Kiessling KW: Interferon-mediated protection of normal and tumor target cells against lysis by mouse natural killer cells. J Immunol 126:219-225, 1981
23. Serreze DV, Hamaguchi K, Leiter EH: Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 2:759-776, 1989
24. DeClercq E: Interferon induction by polynucleotides, modified polynucleotides, and polycarboxylates. in Methods in Enzymology. Vol. 78, Pestka S, Ed. New York, Academic, 1987, p. 227-236
25. Serreze DV, Leiter EH: Defective activation of T suppressor cell function in nonobese diabetic mice: potential relation to cytokine deficiencies. J Immunol 140:3801-3807, 1988
26. Onsrud M: Enhancement of suppressor cell generation in human mixed-lymphocyte cultures by interferon. Int Arch Allergy Appl Immunol 67:315-321, 1982
27. Aune TM, Pierce CW: Activation of suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA 79:3808-3812, 1982
28. Inaba K, Kitaura M, Kato T, Watanabe Y, Kawade Y, Muramatsu S: Contrasting effect of α/β and γ-interferons on expression of macrophage Ia antigens. J Exp Med 163:1030-1035, 1986
29. Tite JP, Powell MB, Ruddle NH: Protein antigen-specific Ia-restricted cytolytic T-cells: analysis of frequency, target cell susceptibility, and mechanism of cytolysis. J Immunol 135:25-33, 1985
30. Noronha A, Toscas A, Jensen MA: Interferon-beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27:207-210, 1990
31. Schattner A: Interferons and autoimmunity. Am J Med Sci 295:532-544, 1988
32. Wilson CA, Jacobs C, Baker P, Baskin DG, Dower S, Lernmark A, Toivola B, Vertrees S, Wilson D: IL-1β modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 144:3784-3788, 1990
33. DeMaeyer E, DeMaeyer-Guignaud J: Production of IFN-α by T-cells and modulation of T-cell, B-cell, NK cell activity by interferon. In Interferons and Other Regulatory Cytokines. New York, Wiley & Sons, 1988, p. 221-273
34. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L: IL-12 administration induces Th1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181:817-821, 1995
35. O'Hara RM Jr, Henderson SL, Nagelin A: Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 795:241-249, 1996
36. Wogensen L, Lee M-S, Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of B-cells in nonobese diabetic mice. J Exp Med 179:1379-1384, 1994
37. Pennline KJ, Roque-Gaffney E, Monahan M: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71:169-175, 1994
38. Sobel DO, Zeligs BJ, Bellanti JA: Poly I:C accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes 41:1016-1021, 1992
39. Tamura-Nishimura M, Sasakawa S: De novo protein synthesis is essential to human interferon-gamma gene expression by the stimulation with poly I:poly C. FEBS Lett 261:343-346, 1990
40. Rabinovitch A: Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev 1:215-240, 1993
41. Schwimmbeck PL, Dyrberg T, Oldstone MB: Abrogation of diabetes in BB rats by acute viral infection: association of viral-lymphocyte interactions. J Immunol 140:3394-3400, 1988